Merck's Tulisokibart Produces Strong Mid-Stage Results in Hidradenitis Suppurativa, Setting Up Phase 3 Development Merck has reported positive Phase 2b findings for tulisokibart, an experimental antibody designed to block TL1A, in people with moderate to severe hidradenitis suppurativa. At 16 weeks, two dosing regimens outperformed placebo on the trial's primary measure of clinical response, offering an early signal that a new immune target may have a role in a condition with

AbbVie's Etentamig Clears Key Bar in Late Stage Myeloma Study, Cutting Progression Risk by More Than Half AbbVie has shared early but striking findings from a large late stage trial testing its experimental drug etentamig in people battling a form of blood cancer that keeps coming back despite multiple rounds of treatment. The Chicago area drugmaker reported that patients on the therapy responded at nearly double the rate seen in those given currently available treatment opti